Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Study Overview
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents.
The study duration will be up to 12 months for all participants.
Study details
The study duration will be approximately 12 months for all participants
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Meningococcal Infection, Healthy Volunteers
-
Age: Between 10 Years - 25 Years
-
Gender: All
Inclusion Criteria:
- Aged 18 to 25 years or 10 to 17 years on the day of inclusion
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and judgment of the Investigator.
- Participants who are either unvaccinated with MenACWY vaccine or have received a single previous dose of MenACWY vaccine at least 4 years prior to study enrollment
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Known or suspected congenital or acquired immunodeficiency
- History of any Neisseria meningitidis infection
- At high risk for meningococcal infection during the study
- Individuals with active tuberculosis
- History of Guillain-Barré syndrome
- Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Find a Study Location to Connect
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
